CA2822746A1 - Compositions and methods for treatment of vitiligo - Google Patents
Compositions and methods for treatment of vitiligo Download PDFInfo
- Publication number
- CA2822746A1 CA2822746A1 CA2822746A CA2822746A CA2822746A1 CA 2822746 A1 CA2822746 A1 CA 2822746A1 CA 2822746 A CA2822746 A CA 2822746A CA 2822746 A CA2822746 A CA 2822746A CA 2822746 A1 CA2822746 A1 CA 2822746A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- skin
- rapamycin
- effective amount
- cosmeceutically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 206010047642 Vitiligo Diseases 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title description 12
- 102000008186 Collagen Human genes 0.000 claims abstract description 11
- 108010035532 Collagen Proteins 0.000 claims abstract description 11
- 229920001436 collagen Polymers 0.000 claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 39
- 229960002930 sirolimus Drugs 0.000 claims description 39
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 39
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 15
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 15
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 15
- 210000002752 melanocyte Anatomy 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- 102000016938 Catalase Human genes 0.000 claims description 5
- 108010053835 Catalase Proteins 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 229960000281 trometamol Drugs 0.000 claims description 5
- 230000037319 collagen production Effects 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 41
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- -1 glutathione peroxides Chemical class 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940002683 retin-a Drugs 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102100020873 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 206010064127 Solar lentigo Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Natural products OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 101710088791 Elongation factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000007575 Macadamia integrifolia Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000017011 Mandorlo dulce Nutrition 0.000 description 1
- 244000076313 Mandorlo dulce Species 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000003861 Ribosomal protein S6 Human genes 0.000 description 1
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000011512 eye pigmentation Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- KANINNSSRWMGIP-UHFFFAOYSA-M sodium;butyl 4-hydroxybenzoate;dodecyl sulfate;hexadecan-1-ol;methyl 4-hydroxybenzoate;octadecan-1-ol;propane-1,2-diol;propyl 4-hydroxybenzoate Chemical group [Na+].CC(O)CO.COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1.CCCCOC(=O)C1=CC=C(O)C=C1.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO KANINNSSRWMGIP-UHFFFAOYSA-M 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- GVPDNFYOFKBFEN-UHFFFAOYSA-N trimethyl(octadecoxy)silane Chemical compound CCCCCCCCCCCCCCCCCCO[Si](C)(C)C GVPDNFYOFKBFEN-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01009—Glutathione peroxidase (1.11.1.9)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.
Description
COMPOSITIONS AND METHODS FOR TREATMENT OF VITILIGO
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No.
61/288,688 filed on December 21, 2009, entitled "Compositions and Methods for Treatment of Vitiligo" and U.S. Provisional Patent Application No. 61/315,672 filed March 19, 2010, entitled "Formulations for Skin Cream Compositions" by Sarah Bacus, both of which are hereby incorporated by reference.
TECHNICAL FIELD
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No.
61/288,688 filed on December 21, 2009, entitled "Compositions and Methods for Treatment of Vitiligo" and U.S. Provisional Patent Application No. 61/315,672 filed March 19, 2010, entitled "Formulations for Skin Cream Compositions" by Sarah Bacus, both of which are hereby incorporated by reference.
TECHNICAL FIELD
[0002] The present invention relates to a novel skin composition that stops progression of vitiliga The invention further relates to a composition containing a compound functioning to inhibit T-cell killing in the melanocytes. More specifically, the invention relates to a composition containing rapamycin as an active ingredient. In addition, the invention can contain fibroblast growth factor as an active ingredient. The invention further relates to a composition for promoting the formation of collagen in the skin, wherein the composition comprises the aforementioned compound or compounds. The invention also relates to a method of treating related skin signs of aging (hollowing or sagging of skin) through use of the composition.
BACKGROUND
BACKGROUND
[0003] The aging process has multiple effects on the overall thickness and elasticity of the cells which comprise the skin. As skin ages, the amount of collagen produced is decreased and the type of collagen changes. In addition, the elastin in the skin decreases, the melanin granules collect into areas of dark-colored blemishes, the cells of the skin become older and the layers of expired cells increases. There are some remedies available to address these problems.
Traditionally, retin-A is used to increase collagen production, decrease elastin loss, decrease production of metalloproteases ( which may cause oxidative damage to the skin), disperse SUBSTITUTE SHEET (RULE 26) melanin granules and exfoliate the layers of dead skin cells from the skin.
However, retin-A has some undesirable side effects and requires monitoring of sun exposure while treating skin. There are additional treatments for aging skin such as hydroquinone (bleaches skin and slows melanin production), alpha hydroxy acid (acts similar to retin-A), anti-oxidants (e.g.
Cellex-C, Prevage or Revale). There is a continuing need for the development of skin care products that aid in the appearance of younger, more vibrant, healthy looking skin.
[0004] Vitiligo is an autoimmune disease presenting with progressive loss of skin pigmentation. Vitiligo is a cutaneous disease in which the melanocytes are destroyed in discrete patches, resulting in lightened areas of variable size and location distributed throughout the skin of the body. Melanocytes are cells located in the stratum basale (bottom layer) of the skin's epidermis. They are also located in the eye, ear, meninges, bones and heart.
Melanocytes produce a pigment called melanin, a derivative of the amino acid tyrosine, through the process of melanogenesis. Variations in the activity of melanocytes and the production of melanin is a primary determinant of human skin color. The condition of vitiligo can also affect eye pigmentation and ear ftinction, as melanin is expressed in both the ear and the uveal tract of the eye. The lightened lesions of the skin are immunocompromised and generally have greater susceptibility to the damaging effects of the sun, premature aging and possible cancer of the skin.
The disease strikes about 1% of the world population, generally during teenage years. The progressive loss of melanocytes from depigmenting vitiligo skin is accompanied by cellular infiltrates containing T lymphocytes. Infiltrating cytotoxic T cells with high affinity T cell receptors have likely escaped clonal deletion in the thymus, allowing such T
cells to enter the circulation. It is thought that through the expression of cutaneous lymphocyte antigen, these T
cells home to the skin where they express type 1-cytokine profiles and mediate melanocyte SUBSTITUTE SHEET (RULE 26) apoptosis via the granzyme/perforin pathway. As this condition affects the skin and is readily visible to the public eye, there are many psychological and social problems that can result.
Hence, there is a great need for continuing development of treatments that can be used to minimize the visible consequences of a condition such as vitiligo, as well as other conditions which manifest themselves as discolorations of the skin (aging spots, liver spots, etc.).
SUMMARY OF THE INVENTION
Traditionally, retin-A is used to increase collagen production, decrease elastin loss, decrease production of metalloproteases ( which may cause oxidative damage to the skin), disperse SUBSTITUTE SHEET (RULE 26) melanin granules and exfoliate the layers of dead skin cells from the skin.
However, retin-A has some undesirable side effects and requires monitoring of sun exposure while treating skin. There are additional treatments for aging skin such as hydroquinone (bleaches skin and slows melanin production), alpha hydroxy acid (acts similar to retin-A), anti-oxidants (e.g.
Cellex-C, Prevage or Revale). There is a continuing need for the development of skin care products that aid in the appearance of younger, more vibrant, healthy looking skin.
[0004] Vitiligo is an autoimmune disease presenting with progressive loss of skin pigmentation. Vitiligo is a cutaneous disease in which the melanocytes are destroyed in discrete patches, resulting in lightened areas of variable size and location distributed throughout the skin of the body. Melanocytes are cells located in the stratum basale (bottom layer) of the skin's epidermis. They are also located in the eye, ear, meninges, bones and heart.
Melanocytes produce a pigment called melanin, a derivative of the amino acid tyrosine, through the process of melanogenesis. Variations in the activity of melanocytes and the production of melanin is a primary determinant of human skin color. The condition of vitiligo can also affect eye pigmentation and ear ftinction, as melanin is expressed in both the ear and the uveal tract of the eye. The lightened lesions of the skin are immunocompromised and generally have greater susceptibility to the damaging effects of the sun, premature aging and possible cancer of the skin.
The disease strikes about 1% of the world population, generally during teenage years. The progressive loss of melanocytes from depigmenting vitiligo skin is accompanied by cellular infiltrates containing T lymphocytes. Infiltrating cytotoxic T cells with high affinity T cell receptors have likely escaped clonal deletion in the thymus, allowing such T
cells to enter the circulation. It is thought that through the expression of cutaneous lymphocyte antigen, these T
cells home to the skin where they express type 1-cytokine profiles and mediate melanocyte SUBSTITUTE SHEET (RULE 26) apoptosis via the granzyme/perforin pathway. As this condition affects the skin and is readily visible to the public eye, there are many psychological and social problems that can result.
Hence, there is a great need for continuing development of treatments that can be used to minimize the visible consequences of a condition such as vitiligo, as well as other conditions which manifest themselves as discolorations of the skin (aging spots, liver spots, etc.).
SUMMARY OF THE INVENTION
[0005] Compositions are disclosed for cosmeceuticals that aid in the retardation of the progression of vitiligo. Methods for preparing cosmeceutical compositions for treating vitiligo are also disclosed. More specifically, the methods herein disclose the use of rapamycin for preventing the progression of vitiligo and the use of rapamycin and fibroblast growth factor for promoting collagen formation. In addition, methods for preparing cosmeceutical compositions resulting in a promotion of collagen are also disclosed. More specifically, the methods herein disclose the use of rapamycin and fibroblast growth factor for promoting collagen formation.
[0006] In one aspect of the invention, the composition contains rapamycin in a cosmeceutically acceptable medium/vehicle that functions to reduce T-cell degradation of melanocytes and lessen the visual signs of vitiligo.
[0007] In another aspect of the invention, the composition contains additional ingredients, such as fibroblast growth factor to aid in collagen formation.
[0008] In yet another aspect of the invention, the composition contains vitamin E.
[0009] In additional aspects of the invention, the composition contains tromethamine, glutathione peroxidase, and catalase.
[00101 In one embodiment, the invention is adminstered topically.
SUBSTITUTE SHEET (RULE 26) [0011] In another embodiment, the compositions is formulated as a leave-on product.
[0012] In yet another aspect of the invention, the composition contains about 0.001 to 0.5%
by weight rapamycin.
[00131 In another embodiment, the composition contains about 0.1 to 0.2% by weight rapamycin [00141 In yet another embodiment, the composition contains about 0.15% by weight rapamycin.
100151 In an additional embodiment the composition is used in a method of treating vitiligo involving topical administration of one of the rapamycin compositions disclosed.
100161 In another embodiment, the composition is used in a method of promoting collagen production involving topical administration of one of the rapamycin compositions disclosed [0017] Another embodiment is a method of inhibiting T cells in melanocytes by administering an about 0.1uM to 100 uM of rapamycin composition to the cells.
DESCRIPTION OF THE DRAWINGS
[00181 These and other advantages of the present invention will be readily understood with reference to the following specifications and attached drawings wherein:
[0019] FIG. 1. Western blot of protein expression in Human Hepatocarcinoma, HH, (T-cell lymphoma) cells treated with increasing doses of rapamycin (0.1 ¨ 100 uM).
DETAILED DESCRIPTION
SUBSTITUTE SHEET (RULE 26) [0020] Preferred embodiments of the present invention will be described hereinbelow with reference to the accompanying drawings. In the following description, well-known functions or constructions are not [0021] In one aspect, the present invention is based on the discovery that drugs, such as rapamycin, actively inhibit T-cells and inhibit the process of T-cell maturation in the melanocytes. It has been further discovered that the use of rapamycin in cosmeceutical medium is an effective topical treatment for vitiligo. The response of vitiligo skin cells to treatment with rapamycin over a course of treatment (twice a day application of 2.5 uM
cosmeceutical rapamycin composition) has shown response via reduction of the discoloration and reduction in the progression of the disease. In another aspect of the present invention, the use of rapamycin and fibroblast growth factor (FGF) promotes the production of collagen and reduces the visible effects of aging.
10022] Rapamycin (also called sirolimus) inhibits the response to interleukin-2 (IL-2) and blocks activation of T- and B-cells. Rapamycin binds to the cytosolic protein FK-binding protein 12 (FKBP12) and inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR Complex 1 (mTORC1).
100231 The treatment of vitiligo and the production of collagen with a rapamycin composition, an FGF composition or a rapamycin and FGF composition of the present invention has many desired effects in management of skin and skin disorders, including anti-ageing, anti-wrinkle and/or an anti-cellulite effects, minimizing the appearance of wrinkles, blemishes, skin lines, oily skin, acne, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, age spots, dark circles around eyes, skin pigmentation, topical inflammation, liver spots, pigmented spots, wrinkles, blemishes, skin lines, oily skin, acne, warts, eczema, pruritic SUBSTITUTE SHEET (RULE 26) skin, psoriasis, inflammatory dermatoses, disturbed keratinization, dandruff, bacterial infection, fungal infection, wound healing, body odor, and skin changes associated with aging.
[0024] Cosmetically acceptable vehicle [00251 The composition according to the invention also comprises a dermatologically/cosmetically acceptable vehicle to act as a diluent, dispersant or carrier for the rapamycin. The vehicle can comprise materials commonly employed in skin care products such as water, liquid or solid emollients, silicone oils, emulsifiers, solvents, humectants, thickeners, powders, propellants and the like. Other agents which can be employed in the present application as the dermatologically acceptable vehicle include fibroblast growth factor (FGF), tromethamine, glutathione peroxides, catalase, sphingoid and phospholipid derivatives, antioxidants and vitamins, antiinflammatories, botanical agents, moisturizing agents, skin whitening agents, peptides, caffeine and sunscreens and UV absorbers. Examples of vehicle ingredients include water, glycerin, hydrogenated polyisobutene, cetearyl alcohol, ceteareth-20, macadamia integrifolia seed oil (macademia nut oil), dimethicone, tocopheryl acetate, stearoxytrimethylsilane, stearyl alcohol, panthenol, farnesol, benzyl alcohol, phenoxyethanol, acrylates/C10-30 alkyl acrylate crosspolymer, sodium hydroxide, citric acid for lotions or water, petrolatum, glyceryl polymethacrylate, dicaprylyl ether, glycerin, dimethicone, glyceryl stearate, cetyl alcohol, prunus amygdalus dulcis (sweet almond) oil, PEG-30 glyceryl stearate, tocopheryl acetate, benzyl alcohol, phenoxyethanol, sodium hydroxide, acrylates/C10-30 alkyl acrylate crosspolymer, disodium EDTA, propylene glycol for creams. A preferred vehicle is Cetaphil .
Examples of some of the agents that can be added to the vehicle include:
sphingoid and phospholipid derivatives (e.g. ceramides, phytosphingosine, sphingosine, pseudoceramides, phospholipids, lysophospholipids); antioxidants and vitamins (e.g. tocopherol and derivatives, SUBSTITUTE SHEET (RULE 26) ascorbic acid and derivatives, niacinamide and derivatives, vitamin complexes, alpha-lipoic acid, retinol and derivatives, panthenol); antiinfiammatories (e.g. bisabolol, allantoin, phytantriol, Coenzyme Q10, Idebenone); botanical agents such as polyphenolics, flavonoids or isofiavones;
moisturizing agents (e.g. amino acids, hyaluronic acid and derivatives, creatine and derivatives, trimethylglycine, myoinositol, pyroglutamatic acid and derivatives, taurine, guanidine and derivatives and hydroxy acids); skin whitening agents (e.g. kojic acid, arbutin, vitamin C and derivatives, hydroquinone); peptides, modified peptides, protein hydrolysates.
[00261 Formulation Table Rapamycin (FW=914.17) 200 mg in 500 ul DMSO (0.4 mg/up Desired Desired Total Amount Amount Amount of Stock Conc. Percent Volume/Mass Active Active Conc. (% Desired Ingredient Ingredient w/v) (mgs) 0.005 0.5 15 gms 0.075 gms 75 mgs 187.5 uls of the 0.4 0.001 0.1 15 gms 0.015 gms 15 mgs 37.5 uls of the 0.4 0.0005 0.05 15 gms 0.0075 gms 7.5 mgs 18.75 uls of the 0.4 0.0001 0.01 15 gms 0.0015 gms 1.5 mgs 3.75 uls of the 0.4 0.00005 0.005 15 gms 0.00075 gms 0.75 mgs 1.875 uls of the 0.4 [00271 The cosmeceutically effective amount of rapamycin that is used in the cosmeceutically acceptable composition has a concentration of about 0.5% to 0.00001%
rapamycin preferably from about 0.5% to 0.1%. The cosmeceutically effective amount of rapamycin is partially dependent on the cells or the individual being treated and higher concentrations may be necessary to achieve desired results, in addition higher concentrations may result in increased side effects. The Formulation Table shows exemplary calculations for producing products of 0.01% and 0.005% rapamycin, similar calculations can be used to produce a cosmeceutically acceptable composition at the desired concentration. For example some SUBSTITUTE SHEET (RULE 26) preferred amounts of ingredients that may be used in any combination in the composition with gms of vehicle are indicated: addition of about 15 mgs of rapamycin is preferred (about 0.15% by weight), addition of about 0.5 ugm to about 1.5 ugm of fibroblast growth factor is preferred (about 0.00005% to 0.00015% by weight), addition of about 0.5 gins of tromethamine is preferred (about 0.5% by weight), addition of about 30 mgs of glutathione peroxides is preferred (about 0.3% by weight), addition of about 30 mgs of catalase is preferred (about 0.3%
by weight), and addition of about 500 mgs of vitamin E is preferred (about 0.5% by weight).
[0028] The dermatologically acceptable vehicle will usually form from about 80% to about 99.999%, preferably from about 95% to about 99.985% and most preferably about 99.985% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition. In a preferred embodiment, the rapamycin is maintained at a concentration of about 0.15% by weight in a cosmeceutically acceptable medium. In another preferred embodiment, the fibroblast growth factor is maintained at a therapeutically effective concentration of about 0.000015% to about 0.00005% in a cosmeceutically acceptable medium.
In another embodiment, the rapamycin and FGF together, comprise about 0.15% by weight in a cosmeceutically acceptable medium.
[0029] The skin care formulation can be an aqueous solution, a water-in-oil (w/o) emulsion, an oil-in-water (o/w) emulsion, a dispersion of lipids, an aqueous, water-alcohol, oil or oil-alcohol gel, a solid stick, a wet-wipe or an aerosol. If the dermatologically acceptable vehicle itself is an (w/o) or (o/w) emulsion, it can contain 5 to 50% of an oilphase and 47 to 94.95%
water, with respect to the weight of the whole formulation.
[0030] Product Preparation, Form, Use and Packaging SUBSTITUTE SHEET (RULE 26) [0031] To prepare the topical composition according to the present invention, the usual manner for preparing skin care products may be employed. The active components are generally incorporated in a dermatologically acceptable carrier in conventional manner.
The active components can suitably be dissolved or dispersed in a portion of the water or another solvent or liquid to be incorporated in the composition. The preferred compositions are oil-in-water or water-in-oil emulsions.
[0032] The composition may be in the form of conventional skin-care products such as a cream, gel or lotion or the like. The composition can also be in the form of a so-called "rinse-off' product, e.g., a bath or shower gel, possibly containing a delivery system for the actives to promote adherence to the skin during rinsing. Most preferably, the product is a "leave-on"
product; a product to be applied to the skin without a deliberate rinsing step soon after its application to the skin.
[0033] The composition may be packaged in any suitable manner such as in ajar, a bottle, tube, roll-ball, or the like, in the conventional manner.
[0034] The active ingredients described in the present invention may be applied one or more times daily to the portion of skin requiring treatment. The improvement in skin appearance will usually become visible after two weeks of treatment, depending on the status of the initial skin condition, the concentration of the active components used in the composition, the volume of composition used and the frequency of application.
[0035] In one embodiment, a small quantity, about 0.25 ml, of the composition is applied to the skin from a suitable container or applicator and spread over and/or rubbed into the skin using the hands or fingers or a suitable device. The composition is formulated as a "leave-on"
product and does not require any gloves or special applicators for effective use. Once applied to SUBSTITUTE SHEET (RULE 26) the skin in the affected area, the composition will begin to elicit the desired effects for treating vitiligo and promoting collagen production.
[0036] Example 1 100371 As shown in Fig. 1, Human Hepatocarcinoma, HH, cells were treated with increasing doses of rapamycin (0.1 ¨ 100 uM) and the protein expression profile was analyzed by Western blot. The rapamycin treatment resulted in increased expression of pAcc (phosphorylated acetyl-CoA carboxylase), slightly increased expression of peEF2 (phosphorylated eukaryotic elongation factor 2) and decreased expression of pS6 (phosphorylated ribosomal protein S6). The expression levels of Actin are maintained and serve as a loading control. The increased expression of pAcc and peEF2, and the decreased expression of pS6 illustrate an inhibition of T-cells.
[0038] Example 2¨ Vitiligostop [0039] Natural sources of anti fungal agents help to stop the rejection of melanin producing cells which causes the depigmentation of the skin. Vitilogstop is not a cure, but provides a noticeable diminishment of discoloration and enlargement of vitiligo spots usually after three months. Combined with other active ingredients, stimulation of new melanin occurs over time. Apply twice a day on affected sites. The cream may oxidize and darken with time but will remain effective throughout use.
Vitilgostop Amount per 10gms Rapamycin 15 milligrams Fibroblast Growth Factor 2 1.5 micrograms Tromethamine 0.5%
Glutathaion Peroxides 30 milligrams Catalase 30 milligrams Vitamin E 500 milligrams Vehicle 10 grams SUBSTITUTE SHEET (RULE 26) 100401 Formulation Example:
[0041] A 0.4 mg/ul Rapamycin composition is made in DMSO as a stock solution, from which an aliquot of 187.5 uls of the stock solution is added to 200 gms of lotion or cosmeceutically acceptable medium and mixed thoroughly. An FGF composition is made following a similar protocol for a cosmeceutically acceptable medium and mixed thoroughly.
Additional concentrations can be made from a concentrated stock solution by methods known to one of ordinary skill in the art. The cosmeceutical formulation (lotion) can be stored at ambient temperature for topical use on those areas of the skin wherein additional lipid production is desired.
100421 While the present invention has been described with respect to what is presently considered to be the preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. The scope of the following claims is to be accorded the broadest interpretation so as to encompass all such modifications and equivalent structures and functions.
[0043] All U.S. and foreign patent documents, all articles, brochures, and all other published documents discussed above are hereby incorporated by reference into the Detailed Description of the Preferred Embodiment.
[00101 In one embodiment, the invention is adminstered topically.
SUBSTITUTE SHEET (RULE 26) [0011] In another embodiment, the compositions is formulated as a leave-on product.
[0012] In yet another aspect of the invention, the composition contains about 0.001 to 0.5%
by weight rapamycin.
[00131 In another embodiment, the composition contains about 0.1 to 0.2% by weight rapamycin [00141 In yet another embodiment, the composition contains about 0.15% by weight rapamycin.
100151 In an additional embodiment the composition is used in a method of treating vitiligo involving topical administration of one of the rapamycin compositions disclosed.
100161 In another embodiment, the composition is used in a method of promoting collagen production involving topical administration of one of the rapamycin compositions disclosed [0017] Another embodiment is a method of inhibiting T cells in melanocytes by administering an about 0.1uM to 100 uM of rapamycin composition to the cells.
DESCRIPTION OF THE DRAWINGS
[00181 These and other advantages of the present invention will be readily understood with reference to the following specifications and attached drawings wherein:
[0019] FIG. 1. Western blot of protein expression in Human Hepatocarcinoma, HH, (T-cell lymphoma) cells treated with increasing doses of rapamycin (0.1 ¨ 100 uM).
DETAILED DESCRIPTION
SUBSTITUTE SHEET (RULE 26) [0020] Preferred embodiments of the present invention will be described hereinbelow with reference to the accompanying drawings. In the following description, well-known functions or constructions are not [0021] In one aspect, the present invention is based on the discovery that drugs, such as rapamycin, actively inhibit T-cells and inhibit the process of T-cell maturation in the melanocytes. It has been further discovered that the use of rapamycin in cosmeceutical medium is an effective topical treatment for vitiligo. The response of vitiligo skin cells to treatment with rapamycin over a course of treatment (twice a day application of 2.5 uM
cosmeceutical rapamycin composition) has shown response via reduction of the discoloration and reduction in the progression of the disease. In another aspect of the present invention, the use of rapamycin and fibroblast growth factor (FGF) promotes the production of collagen and reduces the visible effects of aging.
10022] Rapamycin (also called sirolimus) inhibits the response to interleukin-2 (IL-2) and blocks activation of T- and B-cells. Rapamycin binds to the cytosolic protein FK-binding protein 12 (FKBP12) and inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR Complex 1 (mTORC1).
100231 The treatment of vitiligo and the production of collagen with a rapamycin composition, an FGF composition or a rapamycin and FGF composition of the present invention has many desired effects in management of skin and skin disorders, including anti-ageing, anti-wrinkle and/or an anti-cellulite effects, minimizing the appearance of wrinkles, blemishes, skin lines, oily skin, acne, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, age spots, dark circles around eyes, skin pigmentation, topical inflammation, liver spots, pigmented spots, wrinkles, blemishes, skin lines, oily skin, acne, warts, eczema, pruritic SUBSTITUTE SHEET (RULE 26) skin, psoriasis, inflammatory dermatoses, disturbed keratinization, dandruff, bacterial infection, fungal infection, wound healing, body odor, and skin changes associated with aging.
[0024] Cosmetically acceptable vehicle [00251 The composition according to the invention also comprises a dermatologically/cosmetically acceptable vehicle to act as a diluent, dispersant or carrier for the rapamycin. The vehicle can comprise materials commonly employed in skin care products such as water, liquid or solid emollients, silicone oils, emulsifiers, solvents, humectants, thickeners, powders, propellants and the like. Other agents which can be employed in the present application as the dermatologically acceptable vehicle include fibroblast growth factor (FGF), tromethamine, glutathione peroxides, catalase, sphingoid and phospholipid derivatives, antioxidants and vitamins, antiinflammatories, botanical agents, moisturizing agents, skin whitening agents, peptides, caffeine and sunscreens and UV absorbers. Examples of vehicle ingredients include water, glycerin, hydrogenated polyisobutene, cetearyl alcohol, ceteareth-20, macadamia integrifolia seed oil (macademia nut oil), dimethicone, tocopheryl acetate, stearoxytrimethylsilane, stearyl alcohol, panthenol, farnesol, benzyl alcohol, phenoxyethanol, acrylates/C10-30 alkyl acrylate crosspolymer, sodium hydroxide, citric acid for lotions or water, petrolatum, glyceryl polymethacrylate, dicaprylyl ether, glycerin, dimethicone, glyceryl stearate, cetyl alcohol, prunus amygdalus dulcis (sweet almond) oil, PEG-30 glyceryl stearate, tocopheryl acetate, benzyl alcohol, phenoxyethanol, sodium hydroxide, acrylates/C10-30 alkyl acrylate crosspolymer, disodium EDTA, propylene glycol for creams. A preferred vehicle is Cetaphil .
Examples of some of the agents that can be added to the vehicle include:
sphingoid and phospholipid derivatives (e.g. ceramides, phytosphingosine, sphingosine, pseudoceramides, phospholipids, lysophospholipids); antioxidants and vitamins (e.g. tocopherol and derivatives, SUBSTITUTE SHEET (RULE 26) ascorbic acid and derivatives, niacinamide and derivatives, vitamin complexes, alpha-lipoic acid, retinol and derivatives, panthenol); antiinfiammatories (e.g. bisabolol, allantoin, phytantriol, Coenzyme Q10, Idebenone); botanical agents such as polyphenolics, flavonoids or isofiavones;
moisturizing agents (e.g. amino acids, hyaluronic acid and derivatives, creatine and derivatives, trimethylglycine, myoinositol, pyroglutamatic acid and derivatives, taurine, guanidine and derivatives and hydroxy acids); skin whitening agents (e.g. kojic acid, arbutin, vitamin C and derivatives, hydroquinone); peptides, modified peptides, protein hydrolysates.
[00261 Formulation Table Rapamycin (FW=914.17) 200 mg in 500 ul DMSO (0.4 mg/up Desired Desired Total Amount Amount Amount of Stock Conc. Percent Volume/Mass Active Active Conc. (% Desired Ingredient Ingredient w/v) (mgs) 0.005 0.5 15 gms 0.075 gms 75 mgs 187.5 uls of the 0.4 0.001 0.1 15 gms 0.015 gms 15 mgs 37.5 uls of the 0.4 0.0005 0.05 15 gms 0.0075 gms 7.5 mgs 18.75 uls of the 0.4 0.0001 0.01 15 gms 0.0015 gms 1.5 mgs 3.75 uls of the 0.4 0.00005 0.005 15 gms 0.00075 gms 0.75 mgs 1.875 uls of the 0.4 [00271 The cosmeceutically effective amount of rapamycin that is used in the cosmeceutically acceptable composition has a concentration of about 0.5% to 0.00001%
rapamycin preferably from about 0.5% to 0.1%. The cosmeceutically effective amount of rapamycin is partially dependent on the cells or the individual being treated and higher concentrations may be necessary to achieve desired results, in addition higher concentrations may result in increased side effects. The Formulation Table shows exemplary calculations for producing products of 0.01% and 0.005% rapamycin, similar calculations can be used to produce a cosmeceutically acceptable composition at the desired concentration. For example some SUBSTITUTE SHEET (RULE 26) preferred amounts of ingredients that may be used in any combination in the composition with gms of vehicle are indicated: addition of about 15 mgs of rapamycin is preferred (about 0.15% by weight), addition of about 0.5 ugm to about 1.5 ugm of fibroblast growth factor is preferred (about 0.00005% to 0.00015% by weight), addition of about 0.5 gins of tromethamine is preferred (about 0.5% by weight), addition of about 30 mgs of glutathione peroxides is preferred (about 0.3% by weight), addition of about 30 mgs of catalase is preferred (about 0.3%
by weight), and addition of about 500 mgs of vitamin E is preferred (about 0.5% by weight).
[0028] The dermatologically acceptable vehicle will usually form from about 80% to about 99.999%, preferably from about 95% to about 99.985% and most preferably about 99.985% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition. In a preferred embodiment, the rapamycin is maintained at a concentration of about 0.15% by weight in a cosmeceutically acceptable medium. In another preferred embodiment, the fibroblast growth factor is maintained at a therapeutically effective concentration of about 0.000015% to about 0.00005% in a cosmeceutically acceptable medium.
In another embodiment, the rapamycin and FGF together, comprise about 0.15% by weight in a cosmeceutically acceptable medium.
[0029] The skin care formulation can be an aqueous solution, a water-in-oil (w/o) emulsion, an oil-in-water (o/w) emulsion, a dispersion of lipids, an aqueous, water-alcohol, oil or oil-alcohol gel, a solid stick, a wet-wipe or an aerosol. If the dermatologically acceptable vehicle itself is an (w/o) or (o/w) emulsion, it can contain 5 to 50% of an oilphase and 47 to 94.95%
water, with respect to the weight of the whole formulation.
[0030] Product Preparation, Form, Use and Packaging SUBSTITUTE SHEET (RULE 26) [0031] To prepare the topical composition according to the present invention, the usual manner for preparing skin care products may be employed. The active components are generally incorporated in a dermatologically acceptable carrier in conventional manner.
The active components can suitably be dissolved or dispersed in a portion of the water or another solvent or liquid to be incorporated in the composition. The preferred compositions are oil-in-water or water-in-oil emulsions.
[0032] The composition may be in the form of conventional skin-care products such as a cream, gel or lotion or the like. The composition can also be in the form of a so-called "rinse-off' product, e.g., a bath or shower gel, possibly containing a delivery system for the actives to promote adherence to the skin during rinsing. Most preferably, the product is a "leave-on"
product; a product to be applied to the skin without a deliberate rinsing step soon after its application to the skin.
[0033] The composition may be packaged in any suitable manner such as in ajar, a bottle, tube, roll-ball, or the like, in the conventional manner.
[0034] The active ingredients described in the present invention may be applied one or more times daily to the portion of skin requiring treatment. The improvement in skin appearance will usually become visible after two weeks of treatment, depending on the status of the initial skin condition, the concentration of the active components used in the composition, the volume of composition used and the frequency of application.
[0035] In one embodiment, a small quantity, about 0.25 ml, of the composition is applied to the skin from a suitable container or applicator and spread over and/or rubbed into the skin using the hands or fingers or a suitable device. The composition is formulated as a "leave-on"
product and does not require any gloves or special applicators for effective use. Once applied to SUBSTITUTE SHEET (RULE 26) the skin in the affected area, the composition will begin to elicit the desired effects for treating vitiligo and promoting collagen production.
[0036] Example 1 100371 As shown in Fig. 1, Human Hepatocarcinoma, HH, cells were treated with increasing doses of rapamycin (0.1 ¨ 100 uM) and the protein expression profile was analyzed by Western blot. The rapamycin treatment resulted in increased expression of pAcc (phosphorylated acetyl-CoA carboxylase), slightly increased expression of peEF2 (phosphorylated eukaryotic elongation factor 2) and decreased expression of pS6 (phosphorylated ribosomal protein S6). The expression levels of Actin are maintained and serve as a loading control. The increased expression of pAcc and peEF2, and the decreased expression of pS6 illustrate an inhibition of T-cells.
[0038] Example 2¨ Vitiligostop [0039] Natural sources of anti fungal agents help to stop the rejection of melanin producing cells which causes the depigmentation of the skin. Vitilogstop is not a cure, but provides a noticeable diminishment of discoloration and enlargement of vitiligo spots usually after three months. Combined with other active ingredients, stimulation of new melanin occurs over time. Apply twice a day on affected sites. The cream may oxidize and darken with time but will remain effective throughout use.
Vitilgostop Amount per 10gms Rapamycin 15 milligrams Fibroblast Growth Factor 2 1.5 micrograms Tromethamine 0.5%
Glutathaion Peroxides 30 milligrams Catalase 30 milligrams Vitamin E 500 milligrams Vehicle 10 grams SUBSTITUTE SHEET (RULE 26) 100401 Formulation Example:
[0041] A 0.4 mg/ul Rapamycin composition is made in DMSO as a stock solution, from which an aliquot of 187.5 uls of the stock solution is added to 200 gms of lotion or cosmeceutically acceptable medium and mixed thoroughly. An FGF composition is made following a similar protocol for a cosmeceutically acceptable medium and mixed thoroughly.
Additional concentrations can be made from a concentrated stock solution by methods known to one of ordinary skill in the art. The cosmeceutical formulation (lotion) can be stored at ambient temperature for topical use on those areas of the skin wherein additional lipid production is desired.
100421 While the present invention has been described with respect to what is presently considered to be the preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. The scope of the following claims is to be accorded the broadest interpretation so as to encompass all such modifications and equivalent structures and functions.
[0043] All U.S. and foreign patent documents, all articles, brochures, and all other published documents discussed above are hereby incorporated by reference into the Detailed Description of the Preferred Embodiment.
SUBSTITUTE SHEET (RULE 26)
Claims (13)
1. A composition comprising: a) a cosmeceutically acceptable medium and b) a cosmeceutically effective amount of rapamycin.
2. A composition comprising: a) a cosmeceutically acceptable medium and b) a cosmeceutically effective amount of rapamycin wherein the product reduces the T-cell induced degradation of melanocytes.
3. A composition according to claim 1, further comprising fibroblast growth factor, wherein the composition promotes the formation of collagen.
4. A composition according to claim 1, further comprising vitamin E.
5. A composition according to claim 1, further comprising tromethamine, glutathione peroxidase, and catalase.
6. A composition according to claim 2, wherein said composition is topically administered.
7. A composition according to claim 2, wherein said composition is formulated as a leave-on product.
8. A composition according to claim 2, wherein the product is rapamycin and the cosmeceutically effective amount consists of about 0.001 to 0.5 weight percent of the composition.
9. A composition according to claim 2, wherein the cosmeceutically effective amount consists of about 0.1 to 0.2 weight percent of the composition.
10. A composition according to claim 2, wherein the cosmeceutically effective amount consists of about 0.15 weight percent of the composition.
11. A method of treating vitiligo comprising the step of: topically administering a composition of claim 2 to a person in need thereof.
12. A method of promoting collagen production comprising the step of:
topically administering a composition of claim 2 to a person in need thereof.
topically administering a composition of claim 2 to a person in need thereof.
13. A method of inhibiting T cells in melanocytes comprising the step of:
administering an effective amount of rapamycin to the cells, wherein the effective amount consists of about 0.1 uM to 100 uM.
administering an effective amount of rapamycin to the cells, wherein the effective amount consists of about 0.1 uM to 100 uM.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28868809P | 2009-12-21 | 2009-12-21 | |
US61/288,688 | 2009-12-21 | ||
US31567210P | 2010-03-19 | 2010-03-19 | |
US61/315,672 | 2010-03-19 | ||
PCT/US2010/061661 WO2011079154A1 (en) | 2009-12-21 | 2010-12-21 | Compositions and methods for treatment of vitiligo |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2822746A1 true CA2822746A1 (en) | 2011-06-30 |
Family
ID=44196131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2822746A Abandoned CA2822746A1 (en) | 2009-12-21 | 2010-12-21 | Compositions and methods for treatment of vitiligo |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2515652A4 (en) |
CA (1) | CA2822746A1 (en) |
WO (1) | WO2011079154A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2671583A4 (en) * | 2011-01-31 | 2014-09-03 | Univ Osaka | Externally-used drug for treating skin disorder and method for producing same |
CN102552253A (en) * | 2012-01-17 | 2012-07-11 | 唯美度科技(北京)有限公司 | Skin external agent for eliminating acnes |
CN104324367A (en) * | 2014-10-20 | 2015-02-04 | 广西壮族自治区花红药业股份有限公司 | Novel application of fish scale extract in preparation of medicine for treating and/or preventing leukoderma |
AU2016325446B2 (en) | 2015-09-24 | 2021-05-13 | Drexel University | Novel compositions and methods for treating or preventing dermal disorders |
US10493020B2 (en) | 2016-04-14 | 2019-12-03 | The Procter & Gamble Company | Method of improving the appearance of periorbital dyschromia |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362735A (en) * | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
US6936426B2 (en) * | 2000-10-06 | 2005-08-30 | Harbor-Ucla Research And Education Institute | Detection of antibody mediated inflammatory auto-immune disorders |
WO2002062316A1 (en) * | 2001-02-08 | 2002-08-15 | Vectron Therapeutics Ag | Invasomes for the treatment of disease states, production and use thereof |
US20070026042A1 (en) * | 2005-07-29 | 2007-02-01 | Narayanan Pallasssana V | System for treating aneurysmal disease |
SI2957292T1 (en) * | 2008-03-27 | 2018-04-30 | Clinuvel Pharmaceuticals Limited | Therapy for vitiligo |
-
2010
- 2010-12-21 WO PCT/US2010/061661 patent/WO2011079154A1/en active Application Filing
- 2010-12-21 CA CA2822746A patent/CA2822746A1/en not_active Abandoned
- 2010-12-21 EP EP10840093.8A patent/EP2515652A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2515652A1 (en) | 2012-10-31 |
WO2011079154A1 (en) | 2011-06-30 |
EP2515652A4 (en) | 2014-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8946256B2 (en) | Compositions and methods for treatment of vitiligo | |
CA2907495C (en) | Antioxidant compositions and methods of using the same | |
JP4234137B2 (en) | Preparation of mammalian keratinous tissue using hexamidine composition | |
US6352698B1 (en) | Use of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositions | |
ES2421262T3 (en) | Composition for personal and cosmetic care containing tetrapeptides with CX1X2G, PX1X2P or PX1X2K units | |
ES2259034T3 (en) | USE OF A LIPOIC ACID ENANTIOMER IN COSMETICS AND DERMATOLOGICS. | |
US9387160B2 (en) | Composition and method of treating skin conditions | |
US20070042026A1 (en) | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions | |
JP2002542177A (en) | Methods for regulating the state of keratinous tissue in mammals | |
WO1998053822A1 (en) | Pyridine-thiols reverse mucocutaneous aging | |
JP2005503335A (en) | Skin care composition containing a sugar amine | |
JP2003530302A (en) | Skin care composition containing a combination of skin care actives | |
JP2009508895A (en) | Use of opioid receptor antagonists | |
JP2008156349A (en) | Use of combination of at least one carotenoid with provitamin a activity and at least one carotenoid without provitamin a activity for treating ageing symptom | |
US20110150798A1 (en) | Compositions and methods for increasing cellular far and bleaching skin | |
US20160175223A1 (en) | Anti-aging compositions comprising bile acid-fatty acid conjugates | |
US20110250157A1 (en) | Skin Hyperpigmentation Acyl Glutathione Treatments | |
CA2822746A1 (en) | Compositions and methods for treatment of vitiligo | |
US20030068349A1 (en) | Use of 5'-deoxy-5'-methylthioadenosine in skin cosmetic compositions | |
US20150202187A1 (en) | Compositions and methods for treatment of vitiligo | |
JP2004512295A (en) | Use of a combination of at least one carotenoid and at least one isoflavonoid for treating the signs of skin aging | |
EP2133066A1 (en) | Cosmetic and dermatological composition containing a mixture of retinol derivatives and tocotrienols. | |
JP2002544218A (en) | Methods for adjusting keratin tissue status in mammals | |
WO2011084824A1 (en) | Compositions and methods for increasing cellular fat and bleaching skin | |
WO2012084309A2 (en) | A skin lightening composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20151221 |
|
FZDE | Dead |
Effective date: 20180807 |